Uniphar (UPR) Share Price, News & Analysis

Company Overview

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

Key Stats

• Today's Range: 340 to 350
• 50-Day Range: 311 to 352.60
• 52-Week Range: 163 to 368
• Volume: 10,489 shs
• Average Volume: 50,710 shs
• Market Capitalization: £884.91 million
• P/E Ratio: 1,391.47
• Dividend Yield: 0.01%
• Price Target: GBX 427.50
• Consensus Rating: Moderate Buy

Uniphar Stock Analysis - MarketRank™

Uniphar scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Uniphar has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Uniphar has a consensus price target of GBX 427.50, representing about 25.4% upside from its current price of GBX 340.91.

Amount of Analyst Coverage

Uniphar has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Uniphar is 1,391.47, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 280.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of Uniphar is 1,391.47, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 76.39.

Price to Book Value per Share Ratio

Uniphar has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for UPR.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Uniphar has a dividend yield of 0.48%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Uniphar does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Uniphar is 7.84%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for UPR.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: N/A

News Sentiment

Uniphar has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Uniphar this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Uniphar insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.70% of the stock of Uniphar is held by insiders.

Percentage Held by Institutions

Only 30.91% of the stock of Uniphar is held by institutions.

UPR Stock Analysis - Frequently Asked Questions

How have UPR shares performed this year?

Uniphar's stock was trading at GBX 170.80 at the beginning of the year. Since then, UPR stock has increased by 99.6% and is now trading at GBX 340.91.

How do I buy shares of Uniphar?

Shares of UPR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Uniphar own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Uniphar investors own include IXICO (IXI) and ANGLE (AGL).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Distribution
• Sub-Industry: N/A
• Current Symbol: LON:UPR
• CIK: N/A
• Web: www.uniphar.ie
• Phone: 353 1 428 7777
• Fax: N/A
• Employees: 3,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Uniphar: GBX 427.50
• High Price Target: GBX 480
• Low Price Target: GBX 375
• Potential Upside/Downside: +25.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 0.25
• Trailing P/E Ratio: 1,391.47
• Forward P/E Ratio: 18.11
• P/E Growth: N/A
• Net Income: £51.04 million
• Net Margins: 1.68%
• Pretax Margin: N/A
• Return on Equity: 13.18%
• Return on Assets: 3.76%

Debt

• Debt-to-Equity Ratio: 119.48
• Current Ratio: 0.90
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: £2.89 billion
• Price / Sales: 0.31
• Cash Flow: GBX 34.21 per share
• Price / Cash Flow: 9.97
• Book Value: GBX 127.58 per share
• Price / Book: 2.67

Miscellaneous

• Outstanding Shares: 259,574,000
• Free Float: N/A
• Market Cap: £884.91 million
• Optionable: Not Optionable
• Beta: 0.75